<http://www.diva-portal.org>

Postprint

This is the accepted version of a paper published in *Chemistry - A European Journal*. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the original published paper (version of record):

Verendel, J., Li, J., Quan, X., Peters, B., Zhou, T. et al. (2012)

Chiral Hetero- and Carbocyclic Compounds from the Asymmetric Hydrogenation of Cyclic Alkenes.

Chemistry - A European Journal, 18(21): 6507-6513

<http://dx.doi.org/10.1002/chem.201104073>

Access to the published version may require subscription.

N.B. When citing this work, cite the original published paper.

Permanent link to this version:

<http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-175620>

Chiral hetero- and carbocyclic compounds from the asymmetric hydrogenation of cyclic alkenes

J. Johan Verendel,^[a] Jia-Qi Li,^[a] Xu Quan,^[a] Byron Peters,^[a] Taigang Zhou,^[a] Odd R. Gautun,^[b] Thavendran Govender^[c] and Pher G. Andersson*^{[a],[c]}

Abstract: Several types of chiral hetero- and carbocyclic compounds have been synthesized using the asymmetric hydrogenation of cyclic alkenes. N, P-ligated iridium catalysts reduced six-membered cyclic alkenes with various substituents and heterofunctionality in good to excellent enantioselectivity; whereas the reduction of five-membered cyclic alkenes was generally less selective,

giving modest enantiomeric excesses. The stereoselectivity of hydrogenation depended more strongly on substrate structure for the five- rather than six-membered cyclic alkenes. The major enantiomer formed in the reduction of six-membered alkenes could be predicted from a selectivity model and isomeric alkenes had complementary enantioselectivity, giving opposite optical isomers upon hydrogenation.

The utility of the reaction was demonstrated by using it as a key step in the preparation of chiral 1,3-*cis*-cyclohexane carboxylates.

Keywords: homogeneous catalysis, asymmetric synthesis, iridium, hydrogenation, heterocyclic compounds

Introduction

Chiral hetero- and carbocycles are used in almost every field of chemistry. They are frequently encountered in, for example, pharmaceuticals,^[1] natural products,^[2] fragrances^[3] and molecular switches^[4] as well as in catalysts^[5] and chiral auxiliaries^[6] for organic synthesis. Thus, methods for their enantioselective synthesis are valuable tools for organic chemists. However, the wide range of structural motifs present in chiral hetero- and carbocycles complicates the development of general synthetic methods for their production. The asymmetric hydrogenation using hydrogen gas and a chiral homogeneous catalyst is a powerful tool in organic synthesis^[7] and has potential in the enantioselective synthesis of cyclic molecules because it is among the most general, atom-

efficient and selective methods for producing chiral compounds.^[8] Thus, asymmetric hydrogenation could give access to a broad spectrum of chiral cyclic building blocks if appropriate catalysts were available (Scheme 1).

Scheme 1. General equation for access to chiral heterocycles through the asymmetric hydrogenation of cyclic alkenes.

Several catalytic systems for the asymmetric hydrogenation of *functionalized* cyclic alkenes have been reported. For example, the hydrogenation of 1-aza-2-cycloalkene carboxylates with rhodium- and ruthenium catalysts have yielded chiral 1- or 2-substituted piperidines and piperazines highly selectively.^[9] Zhang and co-workers have reported the asymmetric hydrogenation of β -acetylamino-acrylonitriles^[10] and the group of Szöllösi has performed enantioselective hydrogenation of carboxylate-substituted 3,4-dehydropiperidines^[11] and 5,6-dihydro-2*H*-pyrans.^[12] Non- or weakly-functionalized cyclic alkenes, however, have been much less explored. N,P-ligated iridium complexes of the form $[\text{Ir}(\text{COD})(\text{N}^3\text{P})]^+[\text{BAR}_f]^-$ (COD = 1,5-cyclooctadiene, $[\text{BAR}_f]^- = [(3,5-(\text{F}_3\text{C})_2-\text{C}_6\text{H}_3)_4\text{B}]^-$), originally developed and investigated as asymmetric hydrogenation catalysts by Pfaltz,^[13] are especially promising for this purpose because they can selectively and efficiently add dihydrogen to unfunctionalized double bonds^[14] without relying on an vicinal metal-coordinating group to direct reaction stereochemistry.^[15] Zhou and co-workers used iridium-spiro-

[a] J. J. Verendel, J.-Q. Li, X. Quan, B. Peters, T. Zhou, Prof. P. G. Andersson
Department of Biochemistry and Organic Chemistry
Uppsala University
Box 576, S-75123, Uppsala (Sweden)
Fax: (+46)18 471 3705
E-mail: pher.andersson@biorg.uu.se

[b] Dr. O. R. Gautun
Department of Chemistry
Norwegian University of Science and Technology (NTNU)
NO-7491, Trondheim (Norway)

[c] Prof. T. Govender
School of Chemistry
University of KwaZulu-Natal
Durban, (South Africa)

phosphoramidite complexes to hydrogenate cyclic N-alkyl enamines in high selectivity;^[16] however, only five-membered α -substituted enamides were used. Takaya and co-workers discovered that Ru-BINAP reduced 2-methyl-3,4-dihydrofuran in good selectivity while studying the hydrogenation of alkenes bearing adjacent oxygen functionalities.^[17]

In an initial study, we reported the iridium-catalyzed asymmetric hydrogenation of cyclic alkenes containing tosyl-protected amines.^[18] These were easily obtained from ring-closing metathesis and hydrogenation using N,P-ligated iridium catalysts selectively yielded tosyl-protected chiral pyrrolidines, piperidines and azepanes, typically in greater than 90% *ee* (Scheme 2). Our report was the first on asymmetric hydrogenation of cyclic alkenes of this type and the methodology allowed easy access to azacycles with chiral centers distal to N (Scheme 2).

Scheme 2. The iridium-catalyzed hydrogenation of five-, six-, and seven-membered cyclic alkenes containing an N-Ts heterofunctionality.^[18]

We have now expanded this study to the asymmetric hydrogenation of a broader range of prochiral cyclic alkenes in order to better understand which substrates can be hydrogenated to optically active compounds in high selectivity, and with which catalysts. We have been striving towards revealing the substrate tolerance, mechanistic considerations and synthetic utility of the reaction. Several types of prochiral alkenes, of which the majority have not previously been used in asymmetric hydrogenation, including dihydropyrans, cyclic malonate esters and unsaturated lactones have been reduced highly selectively. Based on the results of this study and a selectivity model,^[19] we also propose a mnemonic device that correctly predicts the absolute configuration of the resulting chiral heteroalkane. The synthesis methodology was applied in the preparation of 1,3-*cis*-cyclohexane carboxylates.

Results and Discussion

The substrates studied here, which include carbo-, aza-, and oxacycles, possessed a range of electronic and steric properties, and we therefore examined an array of iridium-based hydrogenation catalysts (Figure 1). Catalyst class 1 is made up of the sterically similar ligands A-D. Ligands 1A and 1B, in which the coordinating N atom is part of a thiazole moiety, have been used for the asymmetric hydrogenation of unfunctionalized olefins including sterically demanding substrates such as trisubstituted 1,1-diaryl olefins,^[20] vinylphosphonates^[21] and vinylsilanes.^[22] In ligands 1C and 1D, the coordinating N atom is part of an imidazole ring, and is thus more electron-rich than the thiazole nitrogen, producing more electron-rich, less acidic catalysts that are suitable for acid-sensitive substrates such as allylic alcohols and vinyl fluorides.^[23] The ligands in catalyst class 2, with bicyclic backbones and P(o-tol)₂ P-donors, are more sterically demanding than ligands of class 1. These catalysts derive their chirality from amino acids, and have been applied to the iridium-catalyzed asymmetric hydrogenations of imines,^[24] enamines^[25] and vinyl boronates.^[26]

Figure 1. The ligands and corresponding catalysts used in this study.

3,4 – Unsaturated cyclic alkenes

Our initial study showed that several 3-substituted-3,4-dehydropiperidines could be reduced very effectively and stereoselectively, though the optimal catalyst varied with the alkene substituent (Table 1, entries 1 a–g).^[18] Alkenes bearing aromatic substituents (entries 1 a–d) were most effectively reduced using the less bulky, open-backbone ligands of class 1. Notably, the catalyst based on electron-rich ligand 1C gave better yields and *ee* values than 1A for the reduction of alkenes with electron-withdrawing aryl substituents; whereas the opposite was true for 3,4-unsaturated azacycles bearing electron-rich aryl groups. Alkenes with non-aryl substituents (Table 1, entries 1 e–j) were reduced faster and more selectively by catalysts whose ligands had bicyclic backbones (class 2). The same reactivity pattern that was observed for 3-substituted-3,4-dehydropiperidines also applied to 3-substituted 5,6-dihydro-2*H*-pyrans (Table 1, entry 2). 5,6-Dihydro-3-phenyl-2*H*-pyran was hydrogenated in excellent conversion and enantioselectivity using the catalyst with ligand 1A (Table 1, entry 2a). Although this catalyst was also effective for the hydrogenation of the 3-benzyl and 3-hydroxymethyl analogues, these substrates were hydrogenated more selectively when the catalyst was based on ligand 2C. 3,4-Unsaturated carbocycles were also tested in asymmetric hydrogenation. Malonates (entry 3), spirocyclic ketals (entry 4), and ethers (entry 5) were enantioselectively reduced using catalysts based on ligands 1A and 1B (cf. entries 1a and 1e). Catalysts based on ligands from class 2 were less active for the hydrogenation of these alkenes and generally gave lower selectivity.

Table 1. Iridium-catalyzed asymmetric hydrogenation of 3,4-unsaturated six-membered hetero- and carbocycles.

Entry		R	Ligand	conv ^a (%)	ee ^b (%)	
1 ^c		a ^d	Ph	1A	>99	>99 (+)
		b ^d	4-MeOC ₆ H ₄	1A	>99	99 (+)
		c ^d	4-ClC ₆ H ₄	1C	94	98 (+)
		d ^d	4-F ₃ CC ₆ H ₄	1C	74	96 (+)
		e ^d	Me	2A	99	97 (–) (<i>S</i>)
				1B	97	70 (+) (<i>R</i>)
		f ^d	Bn	2A	97	92 (–) (<i>R</i>)
		g ^d	CH ₂ OH	2A	>99	97 (–) (<i>S</i>)
		h	CH ₂ OAc	2C	80	87 (–)
		i	iPr	2C	96	66 (–)
j ^e	OP(O)(OEt) ₂	2B	94	98 (+)		
2 ^c		a	Ph	1A	>99	>99 (+)
		b	CH ₂ OH	2C	>99	96 (–) (<i>R</i>)
		c	Bn	2C	99	92 (+)
3 ^{f,g}		a	Ph	1A	48	>99 (–)
		b	Me	1B	98	98 (–)
4 ^f		a	Ph	1A	>99	>99 (+)
		b	Me	1B	86	96 (–)
5 ^f		a	Ph	1A	>99	>99 (+)
		b	Me	1B	>99	94 (–)

Conditions: 0.25 M substrate in CH₂Cl₂, 15h, r.t. [a] Determined by ¹H NMR spectroscopy; see Supporting information for details [b] Determined by chiral chromatography; see Supporting Information for details [c] 0.5 mol% catalyst, 50 bar H₂ [d] See ref. 18 [e] 5 mol% catalyst, 50 bar H₂ [f] 1 mol% catalyst, 100 bar H₂ [g] E = COOMe

Chiral cyclic 3-substituted malonates give access to 3-substituted cyclohexane esters in high *cis* selectivity after decarboxylation and subsequent thermodynamic equilibration (Scheme 3). Krapcho and Weimaster reported that methyl 3-methyl cyclohexane carboxylate could be obtained in 83% *cis* and 17% *trans* form after thermodynamic equilibration with base.^[27] Using their protocol, we obtained 98% of the *cis* diastereomer for the 3-phenyl analogue.

Scheme 3. Preparation of *cis*-3-substituted cyclohexane carboxylates from chiral cyclic malonates.^[27]

The asymmetric hydrogenations of five-membered 3,4-unsaturated hetero- and carbocycles were also tested. Generally, these alkenes were reduced faster, but less selectively, than their six-membered counterparts (Table 2), likely due to their higher ring strain and

lower steric demands, respectively. A similar trend with decrease in selectivity when going from six- to five-membered rings have been observed by Pfaltz and co-workers when performing asymmetric hydrogenation of tetrasubstituted cyclic olefins.^[28] The excellent selectivities observed for the cyclic malonates (entries 3a and b), suggested that the size of the heterofunctionality significantly affected selectivity in the asymmetric hydrogenation of five-membered 3,4-unsaturated cyclics.

Table 2. The iridium-catalyzed hydrogenation of five-membered 3,4-unsaturated hetero- and carbocycles.

Entry	R	Ligand	conv ^a (%)	ee ^b (%)	
1 ^c		a Ph 1B	99	85 (–)	
	b Me 2C	>99	44 (+)		
	c Bn 2C	>99	54 (+)		
2 ^c		Ph 1B	>99	65 (+)	
3 ^c		a Ph 1B	99	99 (–)	
	b Me 1B	99	93 (–)		
4 ^d		Me 2C	69	47 (–)	
	1B	40	80 (+)		

Conditions: 0.25 M substrate in CH₂Cl₂, 50 bar H₂, 15h, r.t. [a] Determined by ¹H NMR spectroscopy; see Supporting Information for details. [b] Determined by chiral chromatography; see Supporting Information for details. [c] 0.5 mol% catalyst [d] 1 mol% catalyst.

In order to further investigate this hypothesis, a dihydropyrrole was prepared with a bulky diphenyl acetyl protecting group (entry 4) rather than a tosyl group (entry 1b). Although no significant improvement was observed using the catalyst containing ligand **2C**, the one based on ligand **1B** gave the reduced alkene in 80% *ee*, as compared to 21% *ee* for the N-tosyl derivative.

Overall, the nature of the heterofunctionality had little effect on the asymmetric hydrogenations of six-membered cyclic olefins, as excellent enantioselectivities were obtained for most of these substrates. However, the presence of very sterically demanding alkene substituents such as ⁱPr decreased selectivity (Table 1, entry 1i). Heterofunctionality had a greater impact on the asymmetric hydrogenation of olefins in five-membered rings; the bulky dimethylmalonate functionality gave the best results. This group likely inhibited inverted substrate coordination, favoring stereoselectivity.

2, 3-Unsaturated cyclic alkenes

Next, we evaluated the hydrogenation of cyclic alkenes with a heteroatom or substituted carbon atom bound directly to the olefin. These substrates proved more difficult to reduce than their 3,4-unsaturated counterparts, and

often had to be reduced under harsher conditions. Two phenyl-substituted olefins, *N*-tosyl-3-phenyl-2,3-dehydropiperidine and 5-phenyl-3,4-dihydro-2*H*-pyran (Table 3 entries 1a and 2), were reduced in low enantioselectivity by the catalyst containing ligand **1A**, which had performed well for the phenyl-substituted 3,4-unsaturated hetero- and carbocycles. Somewhat better selectivities were obtained using ligands **2A** and **1B**, although the *ee* values remained modest. The 3-methyl derivative (entry 1b) was reduced in 89 % *ee*. We also attempted the hydrogenation of a phosphate-enol ether (entry 1c; cf. Table 1 entry 1j), but when this leaving-group was present on the alkene, *N*-tosyl-piperidine was obtained as the only reaction product.

Table 3. The iridium-catalyzed hydrogenation of six-membered, 2,3-unsaturated hetero- and carbocycles.

Entry		R	Ligand	conv ^a (%)	ee ^b (%)	
1 ^c		a	Ph	1A	20	rac.
		b	Me	2A	21	64 (+)
		c	OP(O)(OEt) ₂	2A	90	89 (+) (<i>R</i>)
Decomposition						
2 ^c		Ph	1A	39	64 (–)	
			1B	29	81 (–)	
3 ^d		Ph	1D	40	66 (–) (<i>S</i>)	
4		a ^e	Ph	1D	>99	94 (–) (<i>S</i>)
		b ^f	Me	1D	>99	92 (–) (<i>S</i>)
		c ^f	Bu	1D	47	88 (–) (<i>S</i>)
5 ^g		a	Ph	1D	15	93 (+) (<i>S</i>)
		b	Me	1D	99	79 (–) (<i>S</i>)

Conditions: 0.25 M substrate in solvent, r.t. [a] Determined by ¹H NMR spectroscopy; see Supporting information for details. [b] Determined by chiral chromatography; see Supporting Information for details. [c] CH₂Cl₂, 0.5 mol% catalyst, 15 h, 50 bar H₂ [d] CH₂Cl₂, 1 mol% catalyst, 15 h, 50 bar H₂, [e] 2,2,2-trifluoroethanol, 1 mol% catalyst, 24 h, 100 bar H₂, [f] CH₂Cl₂, 1 mol% catalyst, 24 h, 50 bar H₂ [g] CH₂Cl₂, 1 mol% catalyst, 24 h, 100 bar H₂.

The asymmetric hydrogenation of one α -substituted enamide (Table 3, entry 3) was also tested but the conversion and selectivity of this reaction were as disappointing as those obtained for the β -substituted enamides. The hydrogenations of α , β -unsaturated cyclic ketones and lactones were also performed. Although high enantioselectivities have been obtained in the transfer hydrogenation of this type of alkenes,^[29] their direct catalytic hydrogenation is less efficient and the few examples reported to date have shown modest selectivity.^[30] Scheuermann née Taylor and Jaekel have developed a rhodium-based system that yields 3-substituted cyclic ketones in moderate to good selectivity^[31] but iridium catalysts have not proven efficient in this reaction. We obtained the target 3-substituted ketones and lactones in high selectivity using catalysts bearing the electron-rich ligand **1D** (Table 3, entries 4 and 5). In the reduction of 3-phenylcyclohex-2-enone, the reaction did not proceed cleanly when performed in CH₂Cl₂. Using simple alcohols (MeOH, EtOH and ⁱPrOH) as solvents gave very low conversion (<10%) of the

starting material. However, when the solvent was the more acidic alcohol 2,2,2-trifluoroethanol, the reaction proceeded satisfactorily, yielding only the desired 3-phenylcyclohex-1-one, fast and in high enantioselectivity (Table 3, entry 4a). For the methyl and butyl derivatives however, the reaction was slower and less selective when performed in 2,2,2-trifluoroethanol as compared to CH₂Cl₂.

Finally, we attempted the hydrogenation of cyclic five-membered 2,3-unsaturated hetero- and carbocycles (Table 4). Good selectivity was obtained for the phenyl-substituted furan (entry 1) and unsaturated lactone (entry 2), although the latter was reduced very slowly. Five-membered cyclic enones were essentially inert to these reaction conditions.

Table 4. The iridium-catalyzed hydrogenation of five-membered, 2,3-unsaturated hetero- and carbocycles.

Entry	R	Ligand	conv ^a (%)	ee ^b (%)	
1 ^c		1C	>99	90 (–)	
2 ^d	a	Ph	2B	20	92 (–) (<i>R</i>)
	b	Me	2C	24	85 (–) (<i>S</i>)

Conditions: 0.25 M substrate in CH₂Cl₂, r.t. [a] Determined by ¹H NMR spectroscopy; see Supporting Information for details. [b] Determined by chiral chromatography; see Supporting Information for details. [c] 1 mol% catalyst, 15 h, 50 bar H₂ [d] 1 mol% catalyst, 24 h, 100 bar H₂.

Origin of enantioselectivity The reduction of a 3-substituted 3,4-unsaturated six-membered heterocycle gives the opposite enantiomer to the reduction of the isomeric 2,3-unsaturated heterocycle. For instance, the asymmetric hydrogenation of *N*-tosyl-3-methyl-3,4-dehydropiperidine (Table 1, entry 1e) using the catalyst derived from ligand **2A** gives the chiral product in the (*S*) configuration, whereas *N*-tosyl-3-methyl-2,3-dehydropiperidine (Table 3, entry 1b) yields the same product, but in the (*R*) configuration. This complementary reaction pattern is especially useful because the iridium catalyst containing ligand **2A** derives its chirality from *tert*-leucine, so one catalyst enantiomer is considerably cheaper to produce than the other. Thus it is fortunate that both enantiomers of the product can be obtained from the same catalyst by using isomeric alkene substrates. This is likely due to the substrate coordination modes shown in Figure 2. Several groups have suggested that the catalyst-alkene complex that exists prior to the enantiodetermining migratory insertion has the structure shown in Figure 2a (drawn for simplicity with ethene as the alkene).^[19a, 32] We have previously used this structure to develop a selectivity model that predicts the absolute configuration of an alkane produced by these hydrogenation catalysts, and this model is based upon the optimal coordination of a trisubstituted alkene to the catalytic pocket.^[19] In the model, shown in Figure 2b, the coordination of a trisubstituted alkene is most favourable when the hydrogen of the alkene is positioned in the most encumbered quadrant. In the case of ligand class **1** (Figure 2b, left), quadrant *iii* is most hindered because it is occupied by the R group on the ligand heterocycle (see Figure

1). The ligand also contributes some steric bulk to quadrant *ii*, whereas quadrants *i* and *iv* are largely unhindered. The bicyclic ligands present in catalyst class **2** have a different shape, and therefore produce a different chiral environment (Figure 2b, right), than those in catalyst class **1**. Here, quadrant *i* is occupied by the heterocycle R-group and consequently most hindered, the P(*o*-tol)₂ group contributes some bulk to quadrant *iv*. As a result, these two catalysts generate the opposite heterocycloalkane enantiomer upon alkene hydrogenation (Figure 2c). This is clear, for example, from the reductions of *N*-tosyl-3-methyl-3,4-dehydropiperidine (Table 1 entry 1e) and *N*-diphenylacetyl-3-methyl-2,5-dihydropyrrole (Table 2, entry 4). The sign of the quasi-dihedral angle θ , between the N-Ir-P plane and the ligand R-group (measured from the position of the incoming alkene), Figure 2b, can be used to determine the absolute configuration of the reaction product. This has been demonstrated for hydrogenation of various trisubstituted alkenes using a large

number of N,P-ligated iridium-catalysts.^[19a] Hence, the reduction of a 3,4-unsaturated cyclic alkenes by a catalyst derived from ligand **1A** ($\theta < 0$) produces one enantiomer of an alkane, and reduction by a catalyst derived from ligand **2B** ($\theta > 0$) gives the other. This model can be used as a mnemonic device to predict the absolute configuration of alkanes produced from the asymmetric hydrogenation of six-membered heterocyclic alkenes, Figure 2c.

Unfortunately, low selectivity and a lack of relevant configuration data in the literature preclude the evaluation of this model in the asymmetric hydrogenation of unsaturated five-membered heterocycles. Nonetheless, it is clear that 3-phenyl-2,5-dihydrofuran (Table 2, entry 2) and 4-phenyl-2,3-dihydrofuran (Table 4, entry 1),

Figure 2. Model explaining the selectivity of heterocycle hydrogenation. Z = H₂ or solvent. a) Catalyst-alkene complex prior to migratory insertion, b) Structure of the open coordination site on the catalyst, as viewed from the perspective of the incoming alkene (some hydrogen atoms have been omitted for clarity), c) Selectivity model for the asymmetric hydrogenation of six-membered heterocyclic alkenes.

give opposite enantiomers upon asymmetric hydrogenation.

Conclusion

Iridium catalysts containing N,P ligands can be used for the highly selective asymmetric hydrogenation of several types of prochiral cyclic alkenes that have not previously been studied. Six-membered 3,4-unsaturated hetero- and carbocycles are reduced with excellent selectivity, largely regardless of the substituent present on the alkene or type of cyclic compound. 2,3-Unsaturated cyclic compounds of the same ring size are reduced most selectively when an electron-withdrawing group is adjacent to the alkene. The reduction of an alkene bearing an electron-withdrawing group within or outside the ring is fastest and most selective when the catalyst bears an electron-rich ligand. The reductions of five-membered cyclic alkenes are, with some exceptions, less selective, giving modest enantiomeric excesses. However, the selectivity in asymmetric hydrogenation of 3,4-unsaturated five-membered heterocycles depends upon the heterofunctionality, so some optimization is possible.

Experimental Section

General procedure for asymmetric hydrogenation of olefins A vial was charged with a magnetic stirrer bar, substrate, iridium catalyst and solvent so that the concentration of the substrate was 0.25 M. The vial was placed in a high-pressure hydrogenation apparatus and the system purged three times with Ar and then filled to the required pressure with H₂. The reaction was stirred at room temperature for the appropriate time before the H₂ was released and the solvent removed in vacuo. Conversion was then determined by ¹H NMR spectroscopy. The crude product was filtered through on a short plug of silica gel and *ee* value determined using chiral GC or HPLC. See supporting information for detailed procedures regarding preparations, analytical methods and characterization data.

Acknowledgements

We are grateful to Dr. Tamara L. Church for a useful discussion. Energimyndigheten (The Swedish Energy Agency), Nordic Energy Research (N-INNER II), The Swedish Research Council (VR), The Knut and Alice Wallenberg Foundation and VR/SIDA supported this work. Odd R. Gautun also acknowledges The Anders Jahres Foundation for financial support.

- [1] Y. K. Agrawal, H. G. Bhatt, H. G. Raval, P. M. Oza and P. J. Gogoi, *Mini-Rev. Med. Chem.* **2007**, *7*, 451-460.
- [2] a) D. O'Hagan, *Nat. Prod. Rep.* **1997**, *14*, 637-651; b) E. Fattorusso and O. Tagliatela-Scafati, *Modern Alkaloids: Structure, Isolation, Synthesis and Biology*, Wiley-VCH, Weinheim, **2008**.
- [3] E. Brenna and C. Fuganti, *Curr. Org. Chem.* **2011**, *15*, 987-1005.
- [4] B. L. Feringa, R. A. van Delden and M. K. J. ter Wiel in *Chiroptical molecular switches*, Vol. (Ed. B. L. Feringa), Wiley-VCH, Weinheim, **2001**, pp. 123-163.
- [5] a) E. N. Jacobsen, A. Pfaltz and H. Yamamoto, *Comprehensive Asymmetric Catalysis*, Springer, Berlin, **1999**; b) A. Dondoni and A. Massi, *Angew. Chem. Int. Ed.* **2008**, *47*, 4638-4660.
- [6] a) M. Benaglia, M. Cinquini and F. Cozzi in *Stereoselective synthesis of enantiomerically pure drugs*, Vol. 7 (Ed. F. Gualtieri), Wiley-VCH, Weinheim, **2000**, pp. 97-138; b) J. Seyden-Penne, *Chiral Auxiliaries and Ligands in Asymmetric Synthesis*, John Wiley & Sons, New York, **1995**.
- [7] a) M. Chang, W. Li, G. Hou and X. Zhang, *Adv. Synth. Catal.* **2010**, *352*, 3121-3125; b) T. Ohkuma, M. Koizumi, H. Doucet, T. Pham, M. Kozawa, K. Murata, E. Katayama, T. Yokozawa, T. Ikariya and R. Noyori, *J. Am. Chem. Soc.* **1998**, *120*, 13529-13530; c) M. C. Perry, X. Cui, M. T. Powell, D.-R. Hou, J. H. Reibenspies and K. Burgess, *J. Am. Chem. Soc.* **2002**, *125*, 113-123; d) C. A. Willoughby and S. L. Buchwald, *J. Am. Chem. Soc.* **1992**, *114*, 7562-7564; e) S. Kaiser, S. P. Smidt and A. Pfaltz, *Angew. Chem. Int. Ed.* **2006**, *45*, 5194-5197.
- [8] a) J.-P. Genet in *Reduction of functionalized alkenes*, Vol. (Eds.: P. G. Andersson and I. J. Munslow), Wiley-VCH, Weinheim, **2008**, pp. 3-38; b) J. S. Diesen and P. G. Andersson in *Hydrogenation of unfunctionalized alkenes*, Vol. (Eds.: P. G. Andersson and I. J. Munslow), Wiley-VCH, Weinheim, **2008**, pp. 39-64.
- [9] a) A. Lei, M. Chen, M. He and X. Zhang, *Eur. J. Org. Chem.* **2006**, 4343-4347; b) R. Kuwano, D. Karube and Y. Ito, *Tetrahedron Lett.* **1999**, *40*, 9045-9049; c) R. Kuwano and Y. Ito, *J. Org. Chem.* **1999**, *64*, 1232-1237; d) K. C. Nicolaou and K. Namoto, *Chem. Commun.* **1998**, 1757-1758; e) I. Karamé, G. Nemra-Baydoun, R. Abdallah, A. Kanj and A. Börner, *Synth. Commun.* **2011**, *41*, 583-588.
- [10] M. Ma, G. Hou, J. Wang and X. Zhang, *Tetrahedron: Asymmetry* **2011**, *22*, 506-511.
- [11] G. Szöllösi, K. Szöri and M. Bartók, *J. Catal.* **2008**, *256*, 349-352.
- [12] K. Szöri, G. Szöllösi and M. Bartók, *New J. Chem.* **2008**, *32*, 1354-1358.
- [13] a) A. Lightfoot, P. Schnider and A. Pfaltz, *Angew. Chem. Int. Ed.* **1998**, *37*, 2897-2899; b) P. Schnider, G. Koch, R. Prétôt, G. Wang, F. M. Bohnen, C. Krüger and A. Pfaltz, *Chem. Eur. J.* **1997**, *3*, 887-892.
- [14] a) X. Cui and K. Burgess, *Chem. Rev.* **2005**, *105*, 3272-3296; b) S. J. Roseblade and A. Pfaltz, *Acc. Chem. Res.* **2007**, *40*, 1402-1411; c) W. Tang, W. Wang and X. Zhang, *Angew. Chem. Int. Ed.* **2003**, *42*, 943-946; d) K. Källström, I. Munslow and P. G. Andersson, *Chem. Eur. J.* **2006**, *12*, 3194-3200.
- [15] a) Y. Zhu and K. Burgess, *Adv. Synth. Catal.* **2008**, *350*, 979-983; b) Y. Fan, X. Cui, K. Burgess and M. B. Hall, *J. Am. Chem. Soc.* **2004**, *126*, 16688-16689; c) T. L. Church and P. G. Andersson, *Coord. Chem. Rev.* **2008**, *252*, 513-531.
- [16] G.-H. Hou, J.-H. Xie, P.-C. Yan and Q.-L. Zhou, *J. Am. Chem. Soc.* **2009**, *131*, 1366-1367.
- [17] T. Ohta, T. Miyake, N. Seido, H. Kumabayashi and H. Takaya, *J. Org. Chem.* **1995**, *60*, 357-363.
- [18] J. J. Verendel, T. Zhou, J.-Q. Li, A. Paptchikhine, O. Lebedev and P. G. Andersson, *J. Am. Chem. Soc.* **2010**, *132*, 8880-8881.
- [19] a) T. L. Church, T. Rasmussen and P. G. Andersson, *Organometallics* **2010**, *29*, 6769-6781; b) C. Hedberg, K. Källström, P. Brandt, L. K. Hansen and P. G. Andersson, *J. Am. Chem. Soc.* **2006**, *128*, 2995-3001.
- [20] P. Tolstoy, M. Engman, A. Paptchikhine, J. Bergquist, T. L. Church, A. W. M. Leung and P. G. Andersson, *J. Am. Chem. Soc.* **2009**, *131*, 8855-8860.
- [21] P. Cheruku, A. Paptchikhine, T. L. Church and P. G. Andersson, *J. Am. Chem. Soc.* **2009**, *131*, 8285-8289.
- [22] K. Källström, I. J. Munslow, C. Hedberg and P. G. Andersson, *Adv. Synth. Catal.* **2006**, *348*, 2575-2578.
- [23] a) P. Kaukoranta, M. Engman, C. Hedberg, J. Bergquist and P. G. Andersson, *Adv. Synth. Catal.* **2008**, *350*, 1168-1176; b) M. Engman, P. Cheruku, P. Tolstoy, J. Bergquist, S. F. Völker and P. G. Andersson, *Adv. Synth. Catal.* **2009**, *351*, 375-378.
- [24] A. Trifonova, J. S. Diesen and P. G. Andersson, *Chem. Eur. J.* **2006**, *12*, 2318-2328.
- [25] P. Cheruku, T. L. Church, A. Trifonova, T. Wartmann and P. G. Andersson, *Tetrahedron Lett.* **2008**, *49*, 7290-7293.
- [26] A. Paptchikhine, P. Cheruku, M. Engman and P. G. Andersson, *Chem. Commun.* **2009**, 5996-5998.
- [27] A. P. Krapcho and J. F. Weimaster, *J. Org. Chem.* **1980**, *45*, 4105-4111.
- [28] A. Schumacher, M. G. Schrems and A. Pfaltz, *Chem. Eur. J.* **2011**, *17*, 13502-13509.
- [29] a) J. B. Tuttle, S. G. Ouellet and D. W. C. MacMillan, *J. Am. Chem. Soc.* **2006**, *128*, 12662-12663; b) B. H. Lipshutz, J. M. Servosko, T. B. Petersen, P. P. Papa and A. A. Lover, *Org. Lett.* **2004**, *6*, 1273-1275; c) G. Hughes, M. Kimura and S. L. Buchwald, *J. Am. Chem. Soc.* **2003**, *125*, 11253-11258; d) N. J. A. Martin and B. List, *J. Am. Chem. Soc.* **2006**, *128*, 13368-13369; e) C. Geiger, P. Kreitmeier and O. Reiser, *Adv. Synth. Catal.* **2005**, *347*, 249-254.
- [30] a) R. Hilgraf and A. Pfaltz, *Adv. Synth. Catal.* **2005**, *347*, 61-77; b) T. Ohshima, H. Tadaoka, K. Hori, N. Sayo and K. Mashima, *Chem. Eur. J.* **2008**, *14*, 2060-2066; c) V. Massonneau, P. Le Maux and G. Simonneaux, *J. Organomet. Chem.* **1987**, *327*, 269-273.
- [31] C. J. Schuermann née Taylor and C. Jaekel, *Adv. Synth. Catal.* **2008**, *350*, 2708-2714.
- [32] a) K. H. Hopmann and A. Bayer, *Organometallics* **2011**, *30*, 2483-2497; b) R. Dietiker and P. Chen, *Angew. Chem. Int. Ed.* **2004**, *43*, 5513-5516; c) P. Brandt, C. Hedberg and P. G. Andersson, *Chem. Eur. J.* **2003**, *9*, 339-347.

Received: ((will be filled in by the editorial staff))

Revised: ((will be filled in by the editorial staff))

Published online: ((will be filled in by the editorial staff))

Entry for the Table of Contents (Please choose one layout only)

Layout 1:

Catch Phrase

*J. Johan Verendel, Jia-Qi Li, Xu Quan, Byron Peters, Taigang Zhou, Odd R. Gautun, Thavendran Govender and Pher G. Andersson**

Chiral hetero- and carbocyclic compounds from the asymmetric hydrogenation of cyclic alkenes

Several types of chiral hetero- and carbocyclic compounds have been synthesized by asymmetric hydrogenation of cyclic alkenes using N, P-ligated iridium catalysts. Six-membered cyclic alkenes were reduced in good to excellent selectivity; whereas the reduction of five-membered cyclic alkenes was generally less selective. The major enantiomer formed could be predicted from a selectivity model and isomeric alkenes had complementary enantioselectivity.